Puretech Health Plc - Adr Share Price (NASDAQ: PRTC)

$17.07

▲

-0.28

(-1.61%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Puretech Health Plc - Adr Stock chart to analyse performance

Puretech Health Plc - Adr stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$17.07
Today's High:$17.33
$17.07
0.0%
Downside
Day's Volatility :1.5%
Upside
1.5%
52 Weeks Low:$13.30
52 Weeks High:$24.99
$17.07
22.09%
Downside
52 Weeks Volatility :46.78%
Upside
31.69%

Puretech Health Plc - Adr Stock Returns

Period	Puretech Health Plc - Adr	Sector (Health Care)	Index (Russel 2000)
3 Months	-6.88%	3.6%	0.0%
6 Months	-5.3%	-7.7%	0.0%
1 Year	-20.14%	-12.6%	0.0%
3 Years	-41.25%	10.2%	-4.1%

Puretech Health Plc - Adr Key Stats

Check Puretech Health Plc - Adr key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$17.35
Open	$17.33
Today's High	$17.33
Today's Low	$17.07
Market Capitalization	$435.8M
Today's Volume	$7.4K
52 Week High	$24.99
52 Week Low	$13.3
Revenue TTM	$4.8M
EBITDA	$-134.1M
Earnings Per Share (EPS)	$1.7
PE Ratio	10.21
Profit Margin	1108.33%
Quarterly Earnings Growth YOY	0.62%
Return On Equity TTM	6.42%

Stock Returns calculator for Puretech Health Plc - Adr Stock including INR - Dollar returns

The Puretech Health Plc - Adr stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Puretech Health Plc - Adr investment value today

Current value as on today

₹83,948

Returns

₹16,052

(-16.05%)

Returns from Puretech Health Plc - Adr Stock

₹21,336 (-21.34%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Puretech Health Plc - Adr Stock

-50%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Puretech Health Plc - Adr Stock from India on INDmoney has decreased by -50% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Puretech Health Plc - Adr

Name
Holdings %
Name
Holdings %
Birch Hill Investment Advisors LLC
1.01%
Millennium Management LLC
0.19%
Pentwater Capital Management LP
0.14%
Portolan Capital Management, LLC
0.12%
Diadema Partners LP
0.03%
Persistent Asset Partners Limited
0.01%

Analyst Recommendation on Puretech Health Plc - Adr Stock

Rating

Trend

Buy

83%Buy

16%Hold

0%Sell

Based on 6 Wall street analysts offering stock ratings for Puretech Health Plc - Adr(by analysts ranked 0 to 5 stars)

Puretech Health Plc - Adr Share Price Target

What analysts predicted

Upside of 169.48%

Target:

$46.00

Current:

$17.07

Puretech Health Plc - Adr share price target is $46.00, a slight Upside of 169.48% compared to current price of $17.07 as per analysts' prediction.

Puretech Health Plc - Adr Stock Insights

Price Movement
In the last 7 days, PRTC stock has moved down by -8.8%
Increasing Revenue
Revenue is up for the last 4 quarters, 90.0K → 4.02M (in $), with an average increase of 60.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -41.77M → 95.28M (in $), with an average increase of 143.8% per quarter
PRTC vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 94.6%
PRTC vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.0% return, outperforming this stock by 156.2%
Price to Sales
ForPRTC every $1 of sales, investors are willing to pay $91.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Puretech Health Plc - Adr Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$8.7M	↓ 46.93%
Net Income	$421.1M	↓ 1064.73%
Net Profit Margin	4.8K%	↑ 5114.07%

	FY20	Y/Y Change
Revenue	$8.3M	↓ 3.99%
Net Income	$4.6M	↓ 98.92%
Net Profit Margin	54.77%	↓ 4792.65%

	FY21	Y/Y Change
Revenue	$10.0M	↑ 19.64%
Net Income	$-62.7M	↓ 1472.79%
Net Profit Margin	-628.41%	↓ 683.18%

	FY22	Y/Y Change
Revenue	$2.1M	↓ 79.06%
Net Income	$-37.1M	↓ 40.9%
Net Profit Margin	-1.8K%	↓ 1144.99%

	FY23	Y/Y Change
Revenue	$3.3M	↑ 59.33%
Net Income	$-65.7M	↑ 77.25%
Net Profit Margin	-2.0K%	↓ 199.48%

	FY24	Y/Y Change
Revenue	$4.3M	↑ 29.58%
Net Income	$53.5M	↓ 181.45%
Net Profit Margin	1.2K%	↑ 3212.97%

Q1 FY23

Q2 FY23

Q3 FY23

Q1 FY24

Q2 FY24

Q1 FY25

	Q1 FY23	Q/Q Change
Revenue	$9.0M	-
Net Income	$-23.1M	-
Net Profit Margin	-256.3%	-

	Q2 FY23	Q/Q Change
Revenue	$3.2M	↓ 65.03%
Net Income	$-25.0M	↑ 8.3%
Net Profit Margin	-793.81%	↓ 537.51%

	Q3 FY23	Q/Q Change
Revenue	$90.0K	↓ 97.14%
Net Income	$-20.3M	↓ 18.63%
Net Profit Margin	-22.6K%	↓ 21813.41%

	Q1 FY24	Q/Q Change
Revenue	$178.6K	↑ 98.41%
Net Income	$-40.4M	↑ 98.41%
Net Profit Margin	-22.6K%	↑ 0.47%

	Q2 FY24	Q/Q Change
Revenue	$288.0K	↑ 61.28%
Net Income	$-41.8M	↑ 3.48%
Net Profit Margin	-14.5K%	↑ 8102.24%

	Q1 FY25	Q/Q Change
Revenue	$4.0M	↑ 1298.26%
Net Income	$95.3M	↓ 328.1%
Net Profit Margin	2.4K%	↑ 16870.61%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-77.2M	↑ 26.43%

	FY20	Y/Y Change
Profit	$8.3M	↓ 110.81%

	FY21	Y/Y Change
Profit	$-100.5M	↓ 1304.8%

	FY22	Y/Y Change
Profit	$-150.3M	↑ 49.61%

	FY23	Y/Y Change
Profit	$-1.6M	↓ 98.93%

	FY24	Y/Y Change
Profit	$4.3M	↓ 369.18%

Q1 FY23

Q2 FY23

Q3 FY23

Q1 FY24

Q2 FY24

Q1 FY25

	Q1 FY23	Q/Q Change
Profit	$-24.9M	-

	Q2 FY23	Q/Q Change
Profit	$89.0K	↓ 100.36%

	Q3 FY23	Q/Q Change
Profit	$-21.5M	↓ 24206.18%

	Q1 FY24	Q/Q Change
Profit	$-1.7M	↓ 92.18%

	Q2 FY24	Q/Q Change
Profit	$-38.6M	↑ 2201.98%

	Q1 FY25	Q/Q Change
Profit	$43.0M	↓ 211.17%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-98.2M	↑ 34.84%
Investing Cash Flow	$63.7M	↓ 260.57%
Financing Cash Flow	$49.9M	↓ 68.19%

	FY20	Y/Y Change
Operating Cash Flow	$-131.8M	↑ 34.3%
Investing Cash Flow	$364.5M	↑ 472.55%
Financing Cash Flow	$38.9M	↓ 22.12%

	FY21	Y/Y Change
Operating Cash Flow	$-158.3M	↑ 20.06%
Investing Cash Flow	$197.4M	↓ 45.85%
Financing Cash Flow	$22.7M	↓ 41.53%

	FY22	Y/Y Change
Operating Cash Flow	$-178.8M	↑ 12.96%
Investing Cash Flow	$-107.2M	↓ 154.32%
Financing Cash Flow	$-29.8M	↓ 231.24%

	FY23	Y/Y Change
Operating Cash Flow	$-105.9M	↓ 40.76%
Investing Cash Flow	$69.0M	↓ 164.34%
Financing Cash Flow	$78.1M	↓ 361.98%

	FY24	Y/Y Change
Operating Cash Flow	$-134.4M	↑ 26.86%
Investing Cash Flow	$240.9M	↑ 249.16%
Financing Cash Flow	$-17.0M	↓ 121.7%

Q1 FY23

Q2 FY23

Q1 FY24

Q2 FY24

Q1 FY25

	Q1 FY23	Q/Q Change
Operating Cash Flow	$-100.3M	↑ 207.97%
Investing Cash Flow	$-105.6M	↓ 221.45%
Financing Cash Flow	$-25.6M	↓ 155.76%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-65.1M	↓ 35.06%
Investing Cash Flow	$173.9M	↓ 264.68%
Financing Cash Flow	$91.9M	↓ 458.66%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-39.9M	↑ 95.87%
Investing Cash Flow	$-105.4M	-
Financing Cash Flow	$-14.4M	↑ 109.03%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-80.0M	↑ 100.32%
Investing Cash Flow	$473.0M	↓ 548.61%
Financing Cash Flow	$-39.1M	↑ 171.97%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-54.4M	↓ 32.07%
Investing Cash Flow	$-232.1M	↓ 149.07%
Financing Cash Flow	$22.1M	↓ 156.63%

Puretech Health Plc - Adr Technicals Summary

Sell

Neutral

Buy

Puretech Health Plc - Adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Puretech Health Plc - Adr Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Puretech Health Plc - Adr	-9.21%	-5.3%	-20.14%	-41.25%	-64.6%
Regeneron Pharmaceuticals, Inc.	3.92%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	2.49%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-15.42%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	11.08%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Puretech Health Plc - Adr	10.21	10.21	NA	-3.8	0.06	-0.13	NA	1.73
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Puretech Health Plc - Adr	Buy	$435.8M	-64.6%	10.21	1108.33%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Puretech Health Plc - Adr

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Organization	Puretech Health Plc - Adr
Employees	56
CEO	Mr. Robert Lyne J.D.
Industry	Health Technology

Key Management of Puretech Health Plc - Adr

Name	Title
Ms. Daphne Zohar	Founder, Senior Advisor & Board Observer
Dr. Robert S. Langer Jr., Ph.D., ScD	Co-Founder & Non-Executive Director
Mr. Robert Lyne J.D.	Interim Chief Executive Officer
Dr. Eric Elenko Ph.D.	Co-Founder & President
Dr. David R. Elmaleh Ph.D.	Co-Founder & Senior Advisor
Ms. Lauren A. White M.B.A.	Chief Financial Officer
Mr. Michael Inbar CPA, M.B.A.	Chief Accounting Officer
Ms. Allison Mead Talbot	Senior VP of Communications & Head of Investor Relations
Mr. Charles Sherwood III, J.D., Ph.D.	General Counsel & Company Secretary
Mr. Spencer Ball	Executive Vice President of Human Resources

Important FAQs about investing in PRTC Stock from India :

What is Puretech Health Plc - Adr share price today?

Puretech Health Plc - Adr share price today is $17.07 as on August 30, 2025 at 1:29 am IST at the close of the market. Puretech Health Plc - Adr share today touched a day high of $17.33 and a low of $17.07.

What is the 52 week high and 52 week low for Puretech Health Plc - Adr share?

Puretech Health Plc - Adr share touched a 52 week high of $24.99 and a 52 week low of $13.30. Puretech Health Plc - Adr stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $17.07, lower by 31.69% versus the 52 week high.

How to invest in Puretech Health Plc - Adr Stock (PRTC) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Puretech Health Plc - Adr on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Puretech Health Plc - Adr Shares that will get you 0.0879 shares as per Puretech Health Plc - Adr share price of $17.07 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Puretech Health Plc - Adr Stock (PRTC) from India?

Indian investors can start investing in Puretech Health Plc - Adr (PRTC) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Puretech Health Plc - Adr stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Puretech Health Plc - Adr share’s latest price of $17.07 as on August 30, 2025 at 1:29 am IST, you will get 0.5858 shares of Puretech Health Plc - Adr. Learn more about fractional shares .

What are the returns that Puretech Health Plc - Adr has given to Indian investors in the last 5 years?

Puretech Health Plc - Adr stock has given -64.6% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?